Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician

References

• Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127–2137.
   PubMed Web of Science ®Google Scholar
• Amor B, Dougados M, Mijiyawa M. Critères de classification des spondylarthropathies [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic. 1990;57:85–89.
   PubMedGoogle Scholar
• Dougados M, Van Der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218–1227.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31.
   PubMed Web of Science ®Google Scholar
• Moltó A, Paternotte S, Comet D, et al. Performances of the assessment of spondyloarthritis international society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional study. Arthritis Care Res (Hoboken). 2013;65:1472–1481.
   PubMed Web of Science ®Google Scholar
• Stolwijk C, Van Tubergen A, Castillo-Ortiz JD, et al. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:65–73.
   PubMed Web of Science ®Google Scholar
• De Winter JJ, van Mens LJ, van der Heijde D, et al. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a metaanalysis. Arthritis Res Ther. 2016;18:196.
   PubMed Web of Science ®Google Scholar
• Dougados M, d’Agostino MA, Benessiano J, et al. The DESIR cohort: a 10- year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine. 2011;78:598–603.
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Liava C, Daoussis D, et al. Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment. World J Gastroenterol. 2019;25(18):2162–2176.
   PubMed Web of Science ®Google Scholar
• Sepriano A, Ramiro S, van der Heijde D, et al. What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. Ann Rheum Dis. 2020;79(3):324–331.
   PubMed Web of Science ®Google Scholar
• Sanchez-Bilbao L, Martinez-Lopez D, Palmou-Fontana N, et al. AB0829. Inflammatory bowel disease in psoriatic arthritis. study of 306 patients from a single University center. prevalence, clinical features and relationship to biologic therapy. Ann Rheumatic Dis. 2020;79:1719.
   Web of Science ®Google Scholar
• Van Praet L, Van Den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;72(3):414–417.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Starr M, Watts C, et al. Detection of Crohn disease in patients with spondyloarthropathy: the SpACE capsule study. J Rheumatol. 2018;45(4):498–505.
   PubMed Web of Science ®Google Scholar
• Essers I, Ramiro S, Stolwijk C, et al. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology (Oxford). 2015;54(4):633–640.
   PubMed Web of Science ®Google Scholar
• Vernero M, Astegiano M, Ribaldone DG. New onset of inflammatory bowel disease in three patients undergoing IL-17A inhibitor Secukinumab: a case series. Am J Gastroenterol. 2019;114(1):179–180.
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, et al. SPIRIT-P1 study group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (Adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146.
   PubMed Web of Science ®Google Scholar
• Peluso R, Di Minno MN, Iervolino S, et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol. 2013;2013:631408.
   PubMedGoogle Scholar
• Rodriguez-Reyna TS, Martinez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol. 2009;15:5517–5524.
   PubMed Web of Science ®Google Scholar
• Palm O, Moum B, Jahnsen J, et al. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford). 2001;40:1256–1261.
   PubMed Web of Science ®Google Scholar
• Ribaldone DG, Vernero M, Parisi S, et al. Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients. Scand J Gastroenterol. 2019;54(10):1233–1236.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Cantini F, Castiglione F, et al. Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev. 2014;13(8):822–830.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Calabrese C, Rizzello F. Inflammatory bowel diseases and spondyloarthropathies. J Rheumatol Suppl. 2015;93:21–23.
   PubMedGoogle Scholar
• Laukens D, Peeters H, Marichal D, et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn’s disease. Ann Rheum Dis. 2005;64:930–935.
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–1463.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Rahman P, Gladman D, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn’s disease. PLoS Genet. 2010;6:e1001195.
   PubMed Web of Science ®Google Scholar
• Coates LC, Baraliakos X, Blanco FJ, et al. the phenotype of axial spondyloarthritis: is it dependent on HLA-B27 status? Arthritis Care Res (Hoboken). 2021;73:856–860.
   PubMed Web of Science ®Google Scholar
• Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol. 2003;30:518–522.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Bombardieri M, Rizzo A, et al. Over-expression of paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal inflammation. Rheumatology (Oxford). 2010;49(11):2076–2083.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Bombardieri M, Principato A, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2009;60(4):955–965.
   PubMed Web of Science ®Google Scholar
• Crane AM, Bradbury L, Van Heel DA, et al. Role of NOD2 variants in spondylarthritis. Arthritis Rheum. 2002;46:1629–1633.
   PubMed Web of Science ®Google Scholar
• Tremelling M, Cummings F, Fisher SA, et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology. 2007;132(5):1657–1664.
   PubMed Web of Science ®Google Scholar
• Roberts AR, Vecellio M, Chen L, et al. An ankylosing spondylitis-associated genetic variant in the IL23R-IL12RB2 intergenic region modulates enhancer activity and is associated with increased Th1-cell differentiation. Ann Rheum Dis. 2016;75:2150–2156.
   PubMedGoogle Scholar
• Turner JE, Stockinger B, Helmby H. IL-22 mediates goblet cell hyperplasia and worm expulsion in intestinal helminth infection. PLoS Pathog. 2013;9:e1003698.
   PubMed Web of Science ®Google Scholar
• Withers DR, Hepworth MR, Wang X, et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat Med. 2016;22(3):319–323.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(9):1739–1747.
   PubMed Web of Science ®Google Scholar
• Hayashi E, Chiba A, Tada K, et al. Involvement of Mucosal-associated invariant T cells in Ankylosing Spondylitis. J Rheumatol. 2016;43(9):1695–1703.
   PubMed Web of Science ®Google Scholar
• Mauro D, Thomas R, Guggino G, et al. Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat Rev Rheumatol. 2021;17(7):387–404.
   PubMed Web of Science ®Google Scholar
• Costello ME, Ciccia F, Willner D, et al. Brief report: intestinal dysbiosis in Ankylosing Spondylitis. Arthritis Rheumatol. 2015;67:686–691.
   PubMed Web of Science ®Google Scholar
• Yin J, Sternes PR, Wang M, et al. Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann Rheum Dis. 2020;79(1):132–140.
   PubMed Web of Science ®Google Scholar
• Mauro D, Ciccia F. Gut dysbiosis in Spondyloarthritis: cause or effect? Best Pract Res Clin Rheumatol. 2019;33(6):101493.
   PubMed Web of Science ®Google Scholar
• Asquith MJ, Stauffer P, Davin S, et al. Perturbed mucosal immunity and dysbiosis accompany clinical disease in a rat model of spondyloarthritis. Arthritis Rheumatol. 2016;68(9):2151–2162.
   PubMed Web of Science ®Google Scholar
• Ruutu M, Thomas G, Steck R, et al. β-glucan triggers spondylarthritis and Crohn’s disease-like ileitis in SKG mice. Arthritis Rheum. 2012;64:2211–2222.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis. 2017;76(6):1123–1132.
   PubMed Web of Science ®Google Scholar
• Gracey E, Vereecke L, McGovern D, et al. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol. 2020;16:415–433.
   PubMed Web of Science ®Google Scholar
• Kragsnaes MS, Kjeldsen J, Horn HC, et al. Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. BMJ Open. 2018;8:e019231.
   PubMed Web of Science ®Google Scholar
• Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• Benfaremo D, Luchetti MM, Gabrielli A. Biomarkers in inflammatory bowel disease-associated spondyloarthritis: state of the art and unmet needs. J Immunol Res. 2019;2019:8630871.
   PubMed Web of Science ®Google Scholar
• Danve A, O’Dell J. The ongoing quest for biomarkers in Ankylosing Spondylitis. Int J Rheum Dis. 2015;18:826–834.
   PubMed Web of Science ®Google Scholar
• Dmowska-Chalaba J, Kontny E. Inflammatory bowel disease-related arthritis - clinical evaluation and possible role of cytokines. Reumatologia. 2015;53:236–242.
   PubMedGoogle Scholar
• Poddubnyy DA, Rudwaleit M, Listing J, et al. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2010;69(1338). LP–1341.
   PubMedGoogle Scholar
• De Vries MK, van Eijk IC, van der Horst-bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti–tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Care Res (Hoboken). 2009;61:1484–1490.
   Web of Science ®Google Scholar
• Prideaux L, De Cruz P, Ng SC, et al. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2011;18:1340–1355.
   PubMed Web of Science ®Google Scholar
• Wallis D, Asaduzzaman A, Weisman M, et al. Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study. Arthritis Res Ther. 2013;15:R166.
   PubMed Web of Science ®Google Scholar
• De Vries M, Van Der Horst-Bruinsma I, Van Hoogstraten I, et al. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease. J Rheumatol. 2010;37:2340–2344.
   PubMed Web of Science ®Google Scholar
• von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007 Apr;1(102):803.
   Google Scholar
• Wagner M, Peterson CGB, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008 Sep 28;14(36):5584–5588.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Björkesten C-GAF, Färkkilä M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol. 2010;45:325–331.
   PubMed Web of Science ®Google Scholar
• Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, et al. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol. 2016;50:147–151.
   PubMed Web of Science ®Google Scholar
• Matzkies FG, Targan SR, Berel D, et al. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther. 2012;14:R261.
   PubMed Web of Science ®Google Scholar
• Østgård RD, Deleuran BW, Dam MY, et al. Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis. Scand J Rheumatol. 2018;47:48–55.
   PubMed Web of Science ®Google Scholar
• Klingberg E, Strid H, Ståhl A, et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017;19:1–9.
   PubMed Web of Science ®Google Scholar
• Fauny M, D’Amico F, Bonovas S, et al. Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review. J Crohns Colitis. 2020;14:688–693.
   PubMed Web of Science ®Google Scholar
• Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheumatism. 1994;37:23–31.
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017Apr29;389(10080):1741–1755. Epub 2016 Dec 1. PMID: 27914655.
   PubMed Web of Science ®Google Scholar
• Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum. 2012;55:773–777.
   PubMed Web of Science ®Google Scholar
• Annunziata ML, Caviglia R, Papparella LG, et al. Upper gastrointestinal involvement of Crohn’s disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci. 2012;57:1618–1623.
   PubMed Web of Science ®Google Scholar
• Harbord M, Annese V, Vavricka SR, et al. European Crohn’s and colitis organisation. The First European Evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohn's Colitis. 2016;10:239–254.
   Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Miehlke S, Guagnozzi D, Zabana Y, et al. European guidelines on microscopic colitis: United European gastroenterology and European microscopic colitis group statements and recommendations. United European Gastroenterol J. 2021. DOI:https://doi.org/10.1177/2050640620951905.
   Google Scholar
• Azzouz D, Gargouri A, Hamdi W, et al. Coexistence of psoriatic arthritis and collagenous colitis with inflammatory nervous system disease. Joint Bone Spine. 2008;75:624–625.
   PubMed Web of Science ®Google Scholar
• Narváez J, Montala N, Busquets-Pérez N, et al. Collagenous colitis and spondylarthropathy. Arthritis Rheum. 2006;55:507–512.
   PubMedGoogle Scholar
• Taccari E, Spada S, Giuliani A, et al. Co-occurrence of psoriatic arthritis with collagenous colitis: clinicopathologic findings of a case. Clin Rheumatol. 2002 Aug;21(4):335–338. PMID: 12189467.
   PubMed Web of Science ®Google Scholar
• Ben Abdelghani K, Sahli H, Souabni L, et al. Collagenous colitis and spondylarthropathy. Case Rep Med. 2012;2012:620241.
   PubMedGoogle Scholar
• Sanz Sanz J, Juanola Roura X, Seoane-Mato D, et al. Grupo de Trabajo del proyecto PIIASER. Screening of inflammatory bowel disease and spondyloarthritis for referring patients between rheumatology and gastroenterology. Gastroenterol Hepatol. 2018;41:54–62.
   PubMed Web of Science ®Google Scholar
• Stebbings S, Jenks K, Treharne GJ, et al. Validation of the dudley inflammatory bowel symptom questionnaire for the assessment of bowel symptoms in axial SpA: prevalence of clinically relevant bowel symptoms and association with disease activity. Rheumatology (Oxford). 2012;51:858–865.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Felice C, Lubrano E, et al. Italian SpA-IBD expert panel group. Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: a Delphi consensus among Italian experts. Dig Liver Dis. 2017;49:1298–1305.
   PubMedGoogle Scholar
• Schreiber S. Certolizumab pegol for the treatment of Crohn’s disease. Therap Adv Gastroenterol. 2011;4:375–389.
   PubMedGoogle Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol. 2005 Sep;19(Suppl A):5A–36A.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010;16:112–124.
   PubMed Web of Science ®Google Scholar
• Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020. DOI:https://doi.org/10.1177/1759720X20939410
   Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. European Crohn’s and Colitis Organisation. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–670.
   PubMed Web of Science ®Google Scholar
• Cypers H, Varkas G, Beeckman S, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016;75:1357–1362.
   PubMed Web of Science ®Google Scholar
• Klingberg E, Carlsten H, Hilme E, et al. Calprotectin in ankylosing spondylitis–frequently elevated in feces, but normal in serum. Scand J Gastroenterol. 2012;47:435–444.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–991.
   PubMed Web of Science ®Google Scholar
• Ribaldone DG, Fagoonee S, Astegiano M, et al. Coxib’s safety in patients with inflammatory bowel diseases: a meta-analysis. Pain Physician. 2015;18:599–607.
   PubMed Web of Science ®Google Scholar
• Dhir V, Mishra D, Samanta J. Glucocorticoids in spondyloarthritis-systematic review and real-world analysis. Rheumatology (Oxford). 2021. DOI:https://doi.org/10.1093/rheumatology/keab275
   Google Scholar
• Carron P, De Craemer A, Van Den Bosch F. Peripheral spondyloarthritis: a neglected entity—state of the art. RMD Open. 2020;6:e001136.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Steenholdt C, Juhl CB, et al. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: a systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine. 2020;20:100271.
   PubMedGoogle Scholar
• Nikfar S, Rahimi R, Rezaie A, et al. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-Aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci. 2009;54:1157–1170.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298(6666):82–86.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14:4–22. PMID: 31711158.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–784.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol. 2013;6:269–293.
   PubMed Web of Science ®Google Scholar
• Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2017;17:879–886.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, Braun J, Baraliakos X, Listing J, et al. Difference in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007;57(4):639–647.
   PubMed Web of Science ®Google Scholar
• O’Toole A, Lucci M, Korzenik J. Inflammatory Bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA. Dig Dis Sci. 2016;61(6):1772–1774.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Watad A, Sharif K, et al. Why inhibition of IL-23 lacked efficacy in Ankylosing Spondylitis. Front Immunol. 2021;12:614255.
   PubMed Web of Science ®Google Scholar
• Baeten D, Østergaard M, Wei J-C-C, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77:1295–1302.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389:1699–1709.
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, Gensler LS, et al. Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71:1599–1613.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM, Fragoulis GE. Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis. Drugs. 2016;76(6):663–673.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM. Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag. 2016;12:1587–1592.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–1700.
   PubMed Web of Science ®Google Scholar
• Fobelo Lozano MJ, Serrano Gimenez R, Castro Fernandez M. Emergence of inflammatory bowel disease during treatment with Secukinumab. J Crohns Colitis. 2018. https://doi.org/10.1093/ecco-jcc/jjy063
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78(4):473–479.
   PubMed Web of Science ®Google Scholar
• Cuthbert RJ, Watad A, Fragkakis EM, et al. Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis. 2019;78(11):1559–1565.
   PubMed Web of Science ®Google Scholar
• Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J Autoimmun. 2018;87:1–15.
   PubMed Web of Science ®Google Scholar
• Lee JS, Tato CM, Joyce-Shaikh B, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity. 2015;43(4):727–738. PMID: 26431948.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721. PMID: 23964933.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. GEMINI 1 study group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Orlando †A, Orlando R, Ciccia F, et al. Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Ann Rheum Dis. 2017;76(9):e31–e31.
   PubMed Web of Science ®Google Scholar
• Tadbiri S, Peyrin-Biroulet L, Serrero M, et al. GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47:485–493.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340–1347.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004–1013.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394:2108–2117.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:2378–2387.
   PubMed Web of Science ®Google Scholar
• Keeling S, Maksymowych WP, Keeling S, Maksymowych WP. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Rev Clin Immunol. 2021;17(7):701–715.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12:1485–1493.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;377:496–497.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Feagan B, Panes J, et al. Safety and efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as induction therapy in patients with Crohn’s disease: results from celest. Gatroenterology. 2017;152(Suppl 1):1308–1309.
   Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–275.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Scriffignano S, Perrotta FM. Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? J Rheumatol. 2019;46(11):1428–1430.
   PubMed Web of Science ®Google Scholar
• Ribaldone DG, Pellicano R, Actis GC. The gut and the inflammatory bowel diseases inside-out: extra-intestinal manifestations. Minerva Gastroenterol Dietol. 2019;65:309–318.
   PubMed Web of Science ®Google Scholar
• Redeker I, Callhoff J, Hoffmann F, et al. Is there an impact of uveitis, psoriasis and inflammatory bowel disease on musculoskeletal disease activity and function in axial spondyloarthritis? [abstract]. Arthritis Rheumatol. 2019;71(suppl):10.
   Google Scholar
• Lubrano E, Parsons WJ, Perrotta FM. Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol. 2016;43(5):918–923.
   PubMed Web of Science ®Google Scholar
• Perrotta FM, Marchesoni A, Lubrano E. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol. 2016;43(2):350–355.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM, Marchesoni A, et al. Remission in non-radiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol. 2015;42:258–263.
   PubMed Web of Science ®Google Scholar